IOVA

Iovance Biotherapeutics, Inc. NASDAQ Listed Oct 15, 2010

Healthcare ·Biotechnology ·US · iovance.com

$4.09

After hrs $4.12 +0.73%

Mkt Cap $1.5B

52w Low $1.64 61.4% of range 52w High $5.63

50d MA $3.81 200d MA $2.77

P/E (TTM) -3.1x

EV/EBITDA -2.4x

P/B 1.7x

Debt/Equity 0.1x

ROE -56.0%

P/FCF -2.9x

RSI (14) —

ATR (14) —

Beta 0.76

50d MA $3.81

200d MA $2.77

Avg Volume 15.7M

About

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candi…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 24, 2026	AMC	-0.22	-0.18	+18.2%	3.78	+10.3%	+1.3%	+0.3%	+2.1%	+0.3%	-0.8%	—
Nov 6, 2025	AMC	-0.29	-0.25	+13.8%	2.31	-2.6%	-0.4%	+2.6%	+14.7%	+10.0%	+4.3%	—
Aug 7, 2025	AMC	-0.29	-0.33	-13.8%	2.64	-27.7%	-20.1%	-25.4%	-15.5%	-7.2%	-7.2%	—
May 8, 2025	AMC	-0.25	-0.36	-44.0%	3.17	-38.8%	-44.8%	-39.1%	-43.5%	-46.1%	-44.5%	—
Feb 27, 2025	AMC	-0.26	-0.26	+0.0%	5.26	-25.3%	-19.4%	-23.2%	-25.5%	-23.0%	-28.7%	—
Nov 7, 2024	AMC	-0.31	-0.28	+9.7%	12.28	-13.1%	-13.8%	-13.3%	-21.1%	-26.7%	-30.0%	—
Aug 8, 2024	AMC	-0.37	-0.34	+8.1%	7.94	+18.3%	+24.9%	+27.1%	+35.3%	+27.3%	+34.4%	—
May 9, 2024	AMC	-0.45	-0.42	+6.7%	13.45	-3.0%	-18.4%	-19.1%	-20.3%	-20.6%	-22.5%	—
Feb 28, 2024	AMC	-0.44	-0.45	-2.3%	17.43	-3.4%	-8.7%	-3.7%	-2.7%	-5.4%	-1.5%	—
Nov 7, 2023	AMC	-0.46	-0.46	+0.0%	4.32	+3.9%	-3.5%	-8.6%	-8.1%	-6.7%	+9.0%	—
Aug 8, 2023	AMC	-0.81	-0.47	+42.0%	7.14	-0.7%	+6.4%	+0.7%	-1.1%	-0.3%	+5.2%	—
May 9, 2023	AMC	-0.84	-0.50	+40.5%	7.36	+3.5%	+3.8%	+1.9%	+1.5%	+6.5%	+1.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 10	Chardan Capital	Maintains	Buy → Buy	—	$4.01	$3.99	-0.5%	-7.7%	-13.7%	-9.2%	-4.7%	-5.2%
Mar 5	UBS	Maintains	Neutral → Neutral	—	$4.26	$4.21	-1.2%	+7.5%	+20.4%	+27.0%	+22.1%	+13.6%
Mar 3	Citizens	Upgrade	Market Perform → Market Outperform	—	$3.79	$3.62	-4.5%	-1.1%	+12.4%	+20.8%	+35.4%	+42.7%
Feb 25	Citizens	Upgrade	Market Perform → Market Outperform	—	$3.78	$4.17	+10.3%	+1.3%	+0.3%	+2.1%	+0.3%	-0.8%
Feb 25	Barclays	Maintains	Overweight → Overweight	—	$3.78	$4.17	+10.3%	+1.3%	+0.3%	+2.1%	+0.3%	-0.8%
Dec 17	Barclays	Maintains	Overweight → Overweight	—	$2.25	$2.26	+0.4%	+12.0%	+9.3%	+10.2%	+23.6%	+25.3%
Nov 24	Barclays	Maintains	Overweight → Overweight	—	$2.24	$2.28	+1.8%	+11.6%	+10.7%	+8.9%	+10.3%	-0.4%
Nov 6	Chardan Capital	Maintains	Buy → Buy	—	$1.81	$2.26	+24.9%	+27.6%	+27.1%	+30.9%	+46.4%	+40.3%
Oct 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.19	$2.16	-1.4%	-8.7%	-11.0%	-10.0%	-11.0%	-16.9%
Aug 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.50	$2.81	+12.4%	+4.0%	+1.2%	+1.6%	+7.6%	+1.2%
Aug 8	Wells Fargo	Maintains	Overweight → Overweight	—	$2.64	$1.91	-27.7%	-20.1%	-25.4%	-15.5%	-7.2%	-7.2%
Aug 8	Chardan Capital	Maintains	Buy → Buy	—	$2.64	$1.91	-27.7%	-20.1%	-25.4%	-15.5%	-7.2%	-7.2%
Jul 23	Chardan Capital	Maintains	Buy → Buy	—	$3.13	$3.75	+19.8%	+26.8%	+5.1%	+0.0%	-5.8%	-6.7%
May 16	UBS	Downgrade	Buy → Neutral	—	$1.76	$1.70	-3.4%	-5.7%	+4.0%	+8.5%	+0.0%	-0.6%
May 12	Goldman Sachs	Maintains	Buy → Buy	—	$1.75	$1.85	+5.7%	+10.3%	+2.3%	-2.3%	+0.6%	-5.1%
May 12	Mizuho	Maintains	Outperform → Outperform	—	$1.75	$1.85	+5.7%	+10.3%	+2.3%	-2.3%	+0.6%	-5.1%
May 12	Barclays	Maintains	Overweight → Overweight	—	$1.75	$1.85	+5.7%	+10.3%	+2.3%	-2.3%	+0.6%	-5.1%
May 9	JMP Securities	Downgrade	Market Outperform → Market Perform	—	$3.17	$1.94	-38.8%	-44.8%	-39.1%	-43.5%	-46.1%	-44.5%
May 9	Chardan Capital	Maintains	Buy → Buy	—	$3.17	$1.94	-38.8%	-44.8%	-39.1%	-43.5%	-46.1%	-44.5%
May 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.17	$1.94	-38.8%	-44.8%	-39.1%	-43.5%	-46.1%	-44.5%
Apr 17	Goldman Sachs	Maintains	Buy → Buy	—	$3.07	$3.05	-0.7%	-0.3%	+0.3%	+4.6%	+3.9%	+9.4%
Apr 14	Barclays	Maintains	Overweight → Overweight	—	$3.30	$3.37	+2.1%	+3.3%	-2.1%	-7.0%	-7.3%	-6.7%
Mar 3	Goldman Sachs	Maintains	Buy → Buy	—	$4.24	$4.27	+0.7%	-4.7%	-7.5%	-4.5%	-11.6%	-11.6%
Mar 3	Truist	Maintains	Buy → Buy	—	$4.24	$4.27	+0.7%	-4.7%	-7.5%	-4.5%	-11.6%	-11.6%
Mar 3	Chardan Capital	Maintains	Buy → Buy	—	$4.24	$4.27	+0.7%	-4.7%	-7.5%	-4.5%	-11.6%	-11.6%
Feb 28	Baird	Maintains	Outperform → Outperform	—	$5.26	$3.93	-25.3%	-19.4%	-23.2%	-25.5%	-23.0%	-28.7%
Feb 28	Piper Sandler	Maintains	Neutral → Neutral	—	$5.26	$3.93	-25.3%	-19.4%	-23.2%	-25.5%	-23.0%	-28.7%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.26	$3.93	-25.3%	-19.4%	-23.2%	-25.5%	-23.0%	-28.7%
Jan 31	Piper Sandler	Maintains	Neutral → Neutral	—	$6.21	$6.12	-1.4%	-5.8%	-9.2%	-6.4%	-1.8%	-5.3%
Nov 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.66	$12.09	+3.7%	+4.1%	+5.3%	-9.2%	-8.7%	-16.9%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.92	$9.97	+0.5%	+1.7%	+8.3%	+1.9%	+7.6%	+5.8%
Jul 29	Piper Sandler	Downgrade	Overweight → Neutral	—	$9.25	$8.43	-8.9%	-2.2%	-3.1%	-5.6%	-11.8%	-15.8%
Jun 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.01	$8.05	+0.5%	+0.1%	+0.6%	-3.5%	-7.7%	-9.1%
Jun 20	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$8.00	$7.82	-2.2%	-0.4%	+0.1%	+2.0%	+5.6%	+1.4%
Jun 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.88	$8.87	-0.1%	-5.7%	-8.8%	-6.3%	-8.3%	-12.4%
May 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.00	$8.99	-0.1%	-1.3%	-7.0%	-10.0%	-7.6%	-9.6%
May 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.26	$10.87	+5.9%	-2.4%	-5.5%	-9.6%	-12.3%	-13.5%
May 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.45	$13.04	-3.0%	-18.4%	-19.1%	-20.3%	-20.6%	-22.5%
Mar 14	Piper Sandler	Maintains	Overweight → Overweight	—	$14.73	$14.70	-0.2%	-3.5%	-5.6%	-4.8%	-5.6%	+1.4%
Mar 7	Truist	Maintains	Buy → Buy	—	$17.16	$17.40	+1.4%	-3.1%	-8.5%	-12.0%	-14.2%	-14.2%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.79	$18.10	+7.8%	+1.0%	-1.8%	+2.2%	-1.0%	-6.5%
Mar 1	Wells Fargo	Maintains	Overweight → Overweight	—	$15.91	$16.36	+2.8%	+5.5%	+6.6%	+3.6%	+7.9%	+4.5%
Feb 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.43	$16.83	-3.4%	-8.7%	-3.7%	-2.7%	-5.4%	-1.5%
Feb 29	Barclays	Maintains	Overweight → Overweight	—	$17.43	$16.83	-3.4%	-8.7%	-3.7%	-2.7%	-5.4%	-1.5%
Feb 29	Goldman Sachs	Maintains	Buy → Buy	—	$17.43	$16.83	-3.4%	-8.7%	-3.7%	-2.7%	-5.4%	-1.5%
Feb 21	Goldman Sachs	Maintains	Buy → Buy	—	$12.03	$12.10	+0.6%	+31.1%	+32.5%	+31.1%	+38.0%	+45.2%
Feb 20	Goldman Sachs	Maintains	Buy → Buy	—	$9.15	$11.65	+27.3%	+31.5%	+72.3%	+74.2%	+72.3%	+81.4%
Feb 20	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$9.15	$11.65	+27.3%	+31.5%	+72.3%	+74.2%	+72.3%	+81.4%
Feb 20	Chardan Capital	Maintains	Buy → Buy	—	$9.15	$11.65	+27.3%	+31.5%	+72.3%	+74.2%	+72.3%	+81.4%
Feb 20	Piper Sandler	Maintains	Overweight → Overweight	—	$9.15	$11.65	+27.3%	+31.5%	+72.3%	+74.2%	+72.3%	+81.4%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

Inovio's executive departure suggests potential leadership instability that could delay clinical programs or vaccine commercialization efforts, creating near-term uncertainty for investors betting on the company's pipeline success.

Mar 20

8-K · 8.01 !! High

Iovance Biotherapeutics, Inc. -- 8-K 8.01: Material Event / Announcement

Iovance Biotherapeutics updated its corporate presentation materials for healthcare conferences and investor meetings, signaling potential strategic updates or progress in its pipeline that management wants to communicate to investors.

Feb 24

Data updated apr 25, 2026 4:01pm · Source: massive.com